First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

Background: We conducted a first-in-human dose-escalation study with the oral FASN inhibitor TVB-2640 to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as monotherapy and with a taxane. Methods: This completed open-label outpatient study was conducted at 11 sites in...

Full description

Bibliographic Details
Main Authors: Gerald Falchook, Jeffrey Infante, Hendrik-Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham Pant, Arthur Frankel, Peter Schmid, Kathleen Moore, William McCulloch, Katharine Grimmer, Marie O'Farrell, George Kemble, Howard Burris
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:EClinicalMedicine
Subjects:
Breast cancer
Gynecological cancers
Lung cancer
Biomarkers
Drug mechanisms
Pharmacology
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537021000778

Similar Items

Similar Items